$BNGO
Bionano Genomics, Inc. Stock $bngo

$bngo Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000141169022000007 Filed on March 01, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$6.302M	$17.98M	$3.990M
YoY Change	57.94%	111.47%	43.06%
Cost Of Revenue	$6.063M	$14.11M	$2.810M
YoY Change	115.77%	146.2%	66.2%
Gross Profit	$239.0K	$3.874M	$1.180M
YoY Change	-79.75%	39.7%	7.43%
Gross Profit Margin	3.79%	21.54%	29.57%
Selling, General & Admin	$18.31M	$58.49M	$9.030M
YoY Change	102.74%	88.26%	54.1%
% of Gross Profit	7659.83%	1509.81%	765.25%
Research & Development	$9.215M	$22.49M	$2.880M
YoY Change	219.97%	119.24%	20.0%
% of Gross Profit	3855.65%	580.41%	244.07%
Depreciation & Amortization	$1.880M	$3.351M	$570.0K
YoY Change	229.82%	126.57%	78.13%
% of Gross Profit	786.61%	86.5%	48.31%
Operating Expenses	$27.52M	$80.98M	$11.91M
YoY Change	131.08%	95.95%	44.19%
Operating Profit	-$27.28M	-$77.10M	-$10.73M
YoY Change	154.27%	100.0%	49.83%
Interest Expense	$30.00K	$927.0K	-$610.0K
YoY Change	-104.92%	-63.2%	-29.89%
% of Operating Profit
Other Income/Expense, Net	$37.00K	-$1.051M	-$10.00K
YoY Change	-470.0%	-58.39%	-101.82%
Pretax Income	-$28.72M	-$78.15M	-$11.74M
YoY Change	144.6%	90.26%	48.8%
Income Tax	-$5.767M	-$5.717M	-$10.00K
% Of Pretax Income
Net Earnings	-$22.95M	-$72.44M	-$11.73M
YoY Change	95.64%	76.22%	48.48%
Net Earnings / Revenue	-364.15%	-402.84%	-293.98%
Basic Earnings Per Share		-$0.26
Diluted Earnings Per Share	-$80.82K	-$261.7K	-$74.66K
COMMON SHARES
Basic Shares Outstanding	289.2M shares	276.8M shares	153.2M shares
Diluted Shares Outstanding		276.8M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$250.6M	$250.6M	$38.45M
YoY Change	551.8%	551.79%	122.25%
Cash & Equivalents	$24.57M	$24.57M	$38.45M
Short-Term Investments	$226.0M	$226.0M	$0.00
Other Short-Term Assets	$2.348M	$4.094M	$462.0K
YoY Change	408.23%	81.96%	1.08%
Inventory	$12.39M	$12.39M	$3.315M
Prepaid Expenses
Receivables	$4.934M	$4.934M	$2.775M
Other Receivables	$387.0K	$387.0K	$0.00
Total Short-Term Assets	$272.4M	$272.4M	$46.79M
YoY Change	482.22%	482.21%	65.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.32M	$20.94M	$4.910M
YoY Change	110.14%	326.37%	151.84%
Goodwill	$56.16M		$7.173M
YoY Change	682.94%
Intangibles	$26.84M		$1.475M
YoY Change	1719.8%
Long-Term Investments
YoY Change
Other Assets	$749.0K	$749.0K	$103.0K
YoY Change	627.18%	649.0%
Total Long-Term Assets	$104.7M	$104.7M	$13.66M
YoY Change	666.31%	666.37%	600.7%
TOTAL ASSETS
Total Short-Term Assets	$272.4M	$272.4M	$46.79M
Total Long-Term Assets	$104.7M	$104.7M	$13.66M
Total Assets	$377.1M	$377.1M	$60.45M
YoY Change	523.82%	523.82%	100.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.696M	$9.696M	$2.930M
YoY Change	230.92%	230.92%	8.55%
Accrued Expenses	$9.694M	$10.48M	$5.599M
YoY Change	73.14%	108.02%	73.59%
Deferred Revenue	$684.0K		$416.0K
YoY Change	64.42%		16.2%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$299.0K	$299.0K	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$21.84M	$21.84M	$8.945M
YoY Change	144.16%	144.3%	-66.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$3.642M	$16.33M
YoY Change	-100.0%	-77.7%
Other Long-Term Liabilities	$14.50M	$14.50M	$0.00
YoY Change		14400.0%	-100.0%
Total Long-Term Liabilities	$0.00	$18.14M	$16.33M
YoY Change	-100.0%	10.42%	36602.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.84M	$21.84M	$8.945M
Total Long-Term Liabilities	$0.00	$18.14M	$16.33M
Total Liabilities	$39.98M	$39.98M	$25.37M
YoY Change	57.61%	57.6%	-4.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$216.1M		-$143.7M
YoY Change	50.41%		40.04%
Common Stock	$553.8M		$178.8M
YoY Change	209.78%		68.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$337.1M	$337.1M	$35.08M
YoY Change
Total Liabilities & Shareholders Equity	$377.1M	$377.1M	$60.45M
YoY Change	523.82%	523.82%	100.11%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$22.95M	-$72.44M	-$11.73M
YoY Change	95.64%	76.22%	48.48%
Depreciation, Depletion And Amortization	$1.880M	$3.351M	$570.0K
YoY Change	229.82%	126.57%	78.13%
Cash From Operating Activities	-$25.62M	-$71.93M	-$12.10M
YoY Change	111.75%	87.73%	27.64%
INVESTING ACTIVITIES
Capital Expenditures	-$478.0K	-$822.0K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$92.03M	-$277.2M	$0.00
YoY Change		11215.92%
Cash From Investing Activities	-$92.51M	-$278.1M	$0.00
YoY Change		11249.47%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.967M	$336.1M	31.68M
YoY Change	-93.79%	442.97%	70.41%
NET CHANGE
Cash From Operating Activities	-25.62M	-$71.93M	-12.10M
Cash From Investing Activities	-92.51M	-$278.1M	0.000
Cash From Financing Activities	1.967M	$336.1M	31.68M
Net Change In Cash	-116.2M	-$13.88M	19.58M
YoY Change	-693.28%	-165.65%	115.4%
FREE CASH FLOW
Cash From Operating Activities	-$25.62M	-$71.93M	-$12.10M
Capital Expenditures	-$478.0K	-$822.0K	$0.00
Free Cash Flow	-$25.14M	-$71.11M	-$12.10M
YoY Change	107.8%	85.58%	27.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001411690
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	2045466000	USD
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38613
CY2021	dei	Entity Registrant Name EntityRegistrantName	Bionano Genomics, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1756290
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	9540 Towne Centre Drive
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2021	dei	City Area Code CityAreaCode	858
CY2021	dei	Local Phone Number LocalPhoneNumber	888-7600
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	289612949	shares
CY2021	dei	Auditor Firm AuditorFirmId	243
CY2021	dei	Auditor Name AuditorName	BDO USA, LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, CA
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24571000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38449000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	226041000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	690000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2119000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4934000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2775000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	12387000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	3315000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4481000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2250000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	272414000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	46789000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10318000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4910000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6691000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3926000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26842000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1475000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	56160000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	7173000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	749000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	103000	USD
CY2021Q4	us-gaap	Assets Assets	377100000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	29000	USD
CY2020Q4	us-gaap	Assets Assets	60450000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9696000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2930000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9694000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5599000	USD
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	684000	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	416000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1467000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	299000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21840000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8945000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5288000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3642000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2021Q4	bngo	Contingent Consideration Fair Value Of Contingent Liability ContingentConsiderationFairValueOfContingentLiability	9066000	USD
CY2020Q4	bngo	Contingent Consideration Fair Value Of Contingent Liability ContingentConsiderationFairValueOfContingentLiability	0	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16325000	USD
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	146000	USD
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	98000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	39982000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	25368000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	289602000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	289602000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	189953000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	189953000	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	19000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	553747000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	178747000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216119000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143684000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-539000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	337118000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	35082000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	377100000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60450000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17981000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8503000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14107000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5730000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22485000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10256000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	58490000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31068000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	80975000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	41324000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-77101000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-38551000	USD
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	236000	USD
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
CY2021	us-gaap	Interest Expense InterestExpense	927000	USD
CY2020	us-gaap	Interest Expense InterestExpense	2519000	USD
CY2021	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	1775000	USD
CY2020	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	0	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2076000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-59000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-41077000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5717000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1051000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2526000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-78152000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-72435000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-41106000	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	276782000	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	104251000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-72435000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-41106000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-539000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72974000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41106000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3613000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1554000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37935000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	40000	USD
CY2020	bngo	Stock Issued During Period Value Covenant Waiver StockIssuedDuringPeriodValueCovenantWaiver	300000	USD
CY2020	bngo	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	28645000	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	4100000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-41106000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	35082000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	602000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9719000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	341023000	USD
CY2021	bngo	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	9418000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	89000	USD
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	14159000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-72435000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-539000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	337118000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-72435000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-41106000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3351000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1479000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	19000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2021	us-gaap	Accretion Expense AccretionExpense	329000	USD
CY2020	us-gaap	Accretion Expense AccretionExpense	0	USD
CY2021	bngo	Noncash Interest Expense NoncashInterestExpense	205000	USD
CY2020	bngo	Noncash Interest Expense NoncashInterestExpense	1264000	USD
CY2021	bngo	Non Cash Lease Expense NonCashLeaseExpense	671000	USD
CY2020	bngo	Non Cash Lease Expense NonCashLeaseExpense	0	USD
CY2021	bngo	Settlement Of Interest On Debt Noncash SettlementOfInterestOnDebtNoncash	1235000	USD
CY2020	bngo	Settlement Of Interest On Debt Noncash SettlementOfInterestOnDebtNoncash	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5777000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	9719000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1554000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1809000	USD
CY2021	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	1775000	USD
CY2020	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	0	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	126000	USD
CY2021	bngo	Gain Loss On Extinguishment Of Debt Cash Expense GainLossOnExtinguishmentOfDebtCashExpense	-1480000	USD
CY2020	bngo	Gain Loss On Extinguishment Of Debt Cash Expense GainLossOnExtinguishmentOfDebtCashExpense	0	USD
CY2021	bngo	Cost Of Leased Equipment Sold To Customer CostOfLeasedEquipmentSoldToCustomer	568000	USD
CY2020	bngo	Cost Of Leased Equipment Sold To Customer CostOfLeasedEquipmentSoldToCustomer	0	USD
CY2021	bngo	Client Warranty Exchange Of Fixed Assets ClientWarrantyExchangeOfFixedAssets	539000	USD
CY2020	bngo	Client Warranty Exchange Of Fixed Assets ClientWarrantyExchangeOfFixedAssets	0	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	66000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	493000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2087000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	15928000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4201000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1971000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	999000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6781000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1810000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3959000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1483000	USD
CY2021	bngo	Payments For Initial Costs On Leases PaymentsForInitialCostsOnLeases	607000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-71927000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38314000	USD
CY2021	bngo	Payments For Property And Equipment PaymentsForPropertyAndEquipment	822000	USD
CY2020	bngo	Payments For Property And Equipment PaymentsForPropertyAndEquipment	0	USD
CY2021	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	638000	USD
CY2020	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	0	USD
CY2020	bngo	Payments For Initial Costs On Leases PaymentsForInitialCostsOnLeases	0	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	313392000	USD
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	86483000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-278062000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2450000	USD
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	15000000	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5000000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
CY2021	bngo	Proceeds From Payroll Protection Program Loan ProceedsFromPayrollProtectionProgramLoan	0	USD
CY2020	bngo	Proceeds From Payroll Protection Program Loan ProceedsFromPayrollProtectionProgramLoan	1774000	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	761000	USD
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2258000	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	342711000	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	39934000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1704000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2000000	USD
CY2021	bngo	Employee Stock Purchase Plan Compensation Expense EmployeeStockPurchasePlanCompensationExpense	89000	USD
CY2020	bngo	Employee Stock Purchase Plan Compensation Expense EmployeeStockPurchasePlanCompensationExpense	40000	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	10020000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	28651000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	336111000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61902000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13878000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21138000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38449000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17311000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24571000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38449000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1910000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1252000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	447000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
CY2021	bngo	Contingent Consideration Noncash ContingentConsiderationNoncash	9000000	USD
CY2020	bngo	Contingent Consideration Noncash ContingentConsiderationNoncash	0	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4751000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021	bngo	Transfer Of Instruments And Servers To Property And Equipment From Inventory TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory	6857000	USD
CY2020	bngo	Transfer Of Instruments And Servers To Property And Equipment From Inventory TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory	4224000	USD
CY2021	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	1775000	USD
CY2020	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	0	USD
CY2021	bngo	Stock Issued For Services StockIssuedForServices	15000	USD
CY2020	bngo	Stock Issued For Services StockIssuedForServices	0	USD
CY2021	bngo	Issue Common Stock For Covenant Waiver IssueCommonStockForCovenantWaiver	0	USD
CY2020	bngo	Issue Common Stock For Covenant Waiver IssueCommonStockForCovenantWaiver	300000	USD
CY2021	bngo	Warrant Exercise Non Cash WarrantExerciseNonCash	129000	USD
CY2020	bngo	Warrant Exercise Non Cash WarrantExerciseNonCash	0	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24600000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	226000000	USD
CY2021Q4	bngo	Working Capital WorkingCapital	250600000	USD
CY2021Q1	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	1800000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions used by management include estimates of selling prices for multiple performance obligation arrangements, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used in purchase accounting and to evaluate the recoverability of long-</span></div>lived assets and goodwill, warranty reserves, certain accrued expenses, contingent liabilities, tax reserves, deferred tax rates and recoverability of the Company’s net deferred tax assets, stock-based compensation expense, and related valuation allowances. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risks</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents and accounts receivable. The Company maintains deposits in federally insured major financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s customers are located throughout the world. The Company generally does not require collateral from its customers. More information on accounts receivable is contained in the paragraph titled “Accounts Receivable” below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sources of Materials and Products</span></div>The materials and components for the Company’s product offerings are currently obtained from single or limited sources. The Company competes with other companies for production capacity, therefore, the Company is exposed to a risk of inventory being unavailable at acceptable prices, or at all, if suppliers are unable (or decide) to provide sufficient levels of materials and components and the Company is unable to identify alternative suppliers.
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	5624000	USD
CY2020Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	4894000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	690000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2119000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4934000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2775000	USD
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	108000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1800000	USD
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	745000	USD
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	2282000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	11642000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1033000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	12387000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	3315000	USD
CY2021	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	800000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.824
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.138
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.023
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.015
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	200000	USD
CY2020Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	200000	USD
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	400000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	400000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2100000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22778000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20464000	shares
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2100000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17981000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8503000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17981000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8503000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	57	lease
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-500000	USD
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	86500000	USD
CY2021	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	-8000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	400000	USD
CY2021Q4	us-gaap	Supplies Supplies	285000	USD
CY2020Q4	us-gaap	Supplies Supplies	1146000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1461000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	642000	USD
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	387000	USD
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	0	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2348000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	462000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4481000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2250000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19390000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12366000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9072000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7456000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10318000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4910000	USD
CY2021	us-gaap	Depreciation Depreciation	1900000	USD
CY2020	us-gaap	Depreciation Depreciation	1400000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	28380000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1538000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	26842000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1580000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	105000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1475000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1400000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5676000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	5676000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	5676000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	5571000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4243000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	26842000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4529000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3251000	USD
CY2021Q4	bngo	Accrued Inventory Current AccruedInventoryCurrent	1073000	USD
CY2020Q4	bngo	Accrued Inventory Current AccruedInventoryCurrent	567000	USD
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	677000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	562000	USD
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1011000	USD
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	358000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	288000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	247000	USD
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	175000	USD
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	113000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	98000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1941000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	403000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9694000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5599000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2100000	USD
CY2019Q1	bngo	Warrants To Purchase Shares Issued WarrantsToPurchaseSharesIssued	200000	shares
CY2019Q2	bngo	Debt Instrument Covenant Maximum Credit Card Indebtedness DebtInstrumentCovenantMaximumCreditCardIndebtedness	200000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	17756000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1430000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	16326000	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	400000	USD
CY2020Q3	bngo	Sale Of Stock Authorized Amount To Be Issued SaleOfStockAuthorizedAmountToBeIssued	125000000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1600000	USD
CY2020Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	18000000	USD
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	33400000	shares
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.05
CY2021Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	101800000	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	300000	USD
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	38300000	shares
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.00
CY2021Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	230000000.0	USD
CY2020Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	27000000	shares
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.82
CY2020Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	22100000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	600000	USD
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	6300000	shares
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.68
CY2021Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	16900000	USD
CY2021Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	400000	USD
CY2021Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2300000	shares
CY2021Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.15
CY2021Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	13900000	USD
CY2021Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	600000	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	24406000	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.76
CY2019	bngo	Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights	P4Y9M25D
CY2019Q4	bngo	Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights	7933000	USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15174000	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.34
CY2020	bngo	Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights	P3Y9M3D
CY2020	bngo	Class Of Warrant Or Right Number Of Securities Granted In Period ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod	95396000	shares
CY2020	bngo	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted In Period ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod	0.22
CY2020	bngo	Class Of Warrant Or Right Weighted Average Remaining Contractual Term Granted In Period Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights	P4Y3M10D
CY2020	bngo	Class Of Warrant Or Right Number Of Securities Exercised In Period ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod	104628000	shares
CY2020	bngo	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised In Period ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod	0.28
CY2020	bngo	Class Of Warrant Or Right Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights	56780000	USD
CY2020	bngo	Class Of Warrant Or Right Number Of Securities Canceled In Period ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod	0	shares
CY2020	bngo	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Canceled In Period ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod	59.90
CY2020Q4	bngo	Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights	26841000	USD
CY2021	bngo	Class Of Warrant Or Right Number Of Securities Granted In Period ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod	0	shares
CY2021	bngo	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted In Period ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod	0
CY2021	bngo	Class Of Warrant Or Right Number Of Securities Exercised In Period ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod	10794000	shares
CY2021	bngo	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised In Period ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod	0.88
CY2021	bngo	Class Of Warrant Or Right Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights	58191000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10178000	USD
CY2021	bngo	Class Of Warrant Or Right Number Of Securities Canceled In Period ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod	24000	shares
CY2021	bngo	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Canceled In Period ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod	3.29
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4356000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.96
CY2021	bngo	Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights	P1Y9M3D
CY2021Q4	bngo	Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights	785000	USD
CY2020Q1	bngo	Class Of Warrant Or Right Number Of Securities Exercised In Period ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod	3200000	shares
CY2020Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5290000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.91
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9108000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.54
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	471000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.30
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2547000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1162000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.90
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12765000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.97
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7891000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3389000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.53
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y1M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4428000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2500000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9719000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1554000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.011
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.006
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.762
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.770
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	59200000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4751000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M6D
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	200000	shares
CY2021	bngo	Lessee Estimated Incremental Borrowing Rate LesseeEstimatedIncrementalBorrowingRate	0.071
CY2021	bngo	Operating Lease Payments Modified And Unmodified OperatingLeasePaymentsModifiedAndUnmodified	447000	USD
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	47000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P19Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.071
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.071
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1118000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	887000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	386000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	0	USD
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	1504000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	887000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	19000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	47000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	USD
CY2021	bngo	Finance Lease Expense FinanceLeaseExpense	66000	USD
CY2020	bngo	Finance Lease Expense FinanceLeaseExpense	0	USD
CY2021	us-gaap	Sublease Income SubleaseIncome	18000	USD
CY2020	us-gaap	Sublease Income SubleaseIncome	422000	USD
CY2021	us-gaap	Lease Cost LeaseCost	1552000	USD
CY2020	us-gaap	Lease Cost LeaseCost	465000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1881000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	314000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1950000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	322000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2011000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	330000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2088000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	338000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	232000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	346000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	5949000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8162000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	7599000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1407000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	3658000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6755000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	3941000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	734000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	639000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	666000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	696000	USD
CY2020Q4	bngo	Operating Leases Future Minimum Payments Due In Four Years And Thereafter OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter	729000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3464000	USD
CY2021Q4	bngo	Contractual Commitment Purchase Of Products Every Quarter ContractualCommitmentPurchaseOfProductsEveryQuarter	300000	USD
CY2021	bngo	Purchase Obligation Initial Purchase Period PurchaseObligationInitialPurchasePeriod	P2Y
CY2021	bngo	Purchase Obligation Contract Termination Period PurchaseObligationContractTerminationPeriod	P90D
CY2021Q4	bngo	Contingent Consideration Fair Value Of Contingent Liability ContingentConsiderationFairValueOfContingentLiability	9100000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	21000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-78356000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-41191000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	204000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	114000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-78152000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-41077000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	39000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	24000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	60000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	29000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4055000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-1722000	USD
CY2020	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5777000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5717000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	938000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	568000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-16000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-16000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-4000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5717000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-16413000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-8626000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2030000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-522000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	12879000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9816000	USD
CY2021	bngo	Effective Income Tax Rate Reconciliation Excessive Employee Remuneration Amount EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount	966000	USD
CY2020	bngo	Effective Income Tax Rate Reconciliation Excessive Employee Remuneration Amount EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount	0	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-165000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-67000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29000	USD
CY2021Q4	bngo	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	7478000	USD
CY2020Q4	bngo	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	350000	USD
CY2021Q4	bngo	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2504000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	81399000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	62354000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6911000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5671000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	849000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	450000	USD
CY2021Q4	bngo	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	2517000	USD
CY2020Q4	bngo	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1457000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2148000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	93133000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70623000	USD
CY2020Q4	bngo	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	0	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	83151000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70273000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	83200000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70300000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4201000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3708000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	231000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	53000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	687000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5119000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	440000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4201000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	830000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	460000	USD

Files In Submission

Name	View Source	Status
0001411690-22-000007-index-headers.html	Edgar Link	pending
0001411690-22-000007-index.html	Edgar Link	pending
0001411690-22-000007.txt	Edgar Link	pending
0001411690-22-000007-xbrl.zip	Edgar Link	pending
bionano-nancyridgeleasee.htm	Edgar Link	pending
bionano-nancyridgeleasee001.jpg	Edgar Link	pending
bionano-nancyridgeleasee002.jpg	Edgar Link	pending
bionano-nancyridgeleasee003.jpg	Edgar Link	pending
bionano-nancyridgeleasee004.jpg	Edgar Link	pending
bionano-nancyridgeleasee005.jpg	Edgar Link	pending
bionano-nancyridgeleasee006.jpg	Edgar Link	pending
bionano-nancyridgeleasee007.jpg	Edgar Link	pending
bionano-nancyridgeleasee008.jpg	Edgar Link	pending
bionano-nancyridgeleasee009.jpg	Edgar Link	pending
bionano-nancyridgeleasee010.jpg	Edgar Link	pending
bionano-nancyridgeleasee011.jpg	Edgar Link	pending
bionano-nancyridgeleasee012.jpg	Edgar Link	pending
bionano-nancyridgeleasee013.jpg	Edgar Link	pending
bionano-nancyridgeleasee014.jpg	Edgar Link	pending
bionano-nancyridgeleasee015.jpg	Edgar Link	pending
bionano-nancyridgeleasee016.jpg	Edgar Link	pending
bionano-nancyridgeleasee017.jpg	Edgar Link	pending
bionano-nancyridgeleasee018.jpg	Edgar Link	pending
bionano-nancyridgeleasee019.jpg	Edgar Link	pending
bngo-1038_bionanoxcommerci.htm	Edgar Link	pending
bngo-20211231.htm	Edgar Link	pending
bngo-20211231.xsd	Edgar Link	pending
bngo-20211231_cal.xml	Edgar Link	unprocessable
bngo-20211231_def.xml	Edgar Link	unprocessable
bngo-20211231_g1.jpg	Edgar Link	pending
bngo-20211231_g2.jpg	Edgar Link	pending
bngo-20211231_g3.jpg	Edgar Link	pending
bngo-20211231_htm.xml	Edgar Link	completed
bngo-20211231_lab.xml	Edgar Link	unprocessable
bngo-20211231_pre.xml	Edgar Link	unprocessable
bngo-ex1034_bionanoxkeyemp.htm	Edgar Link	pending
bngo-ex1035_bionanoxstockr.htm	Edgar Link	pending
bngo-ex1036_bionanoxemploy.htm	Edgar Link	pending
bngo-ex1039_bionanoxfiftha.htm	Edgar Link	pending
bngo-ex107_bionanoxnonxemp.htm	Edgar Link	pending
bngo-ex211_bionanoxsubsidi.htm	Edgar Link	pending
bngo-ex311x20211231.htm	Edgar Link	pending
bngo-ex312x20211231.htm	Edgar Link	pending
bngo-ex321x20211231.htm	Edgar Link	pending
bngo-ex322x20211231.htm	Edgar Link	pending
exhibit231-bdoauditorconse.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BNGO
Bionano Genomics, Inc. Stock $bngo

2021 Q4 Form 10-K Financial Statement

#000141169022000007 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BNGO Bionano Genomics, Inc. Stock $bngo

2021 Q4 Form 10-K Financial Statement

#000141169022000007 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BNGO
Bionano Genomics, Inc. Stock $bngo